Bioequivalence of New Asasantin ER Formulation vs Aggrenox in Healthy Volunteers

Phase 1, randomised, open-label trial of dipyridamole + aspirin in ischemic stroke and Transient Ischemic Attack (TIA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of dipyridamole in plasma over one dosing interval at steady state up to 17 days and Maximum measured concentration of dipyridamole in plasma at steady state up to 17 days. Started Jan 2004; status: completed.